# TaiAn Technologies

> TaiAn Technologies is a VC fund in Taipei backing Biotechnology and Medical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Taipei, Taiwan
- Total investments: 8
- Last investment: Jul 2025
- Lead investor: 13%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/taian-technologies-corporation
- Website: http://www.taiantech.com

TaiAn Technologies is a VC fund in Taipei focused on Biotechnology and Medical. TaiAn Technologies Corporation is a technology advisory company that specializes in commercializing intellectual properties in the life sciences. Our team comprised of numerous biomedical experts that work closely with investment professionals to support up-and-coming life science technologies. Most importantly, we are entrusted by our shareholdersto explore technology platforms in the life sciences arena, to build upon the novel technologies, and to transform them into viable business opportunities supporting existing or creating new entities. Our shareholders comprised of Development Fund of the Executive Yuan of Taiwan as well as numerous conglomerates that are recognized in Taiwan and internationally well known. Leveraging our shareholders/ partners' resources and our strong management team, our multiplex services create synergies with Taiwanese corporations and add significant value to your company.

## Contacts

5 contacts available for TaiAn Technologies. Shizune tracks 4 team members at TaiAn Technologies. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/taian-technologies?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.6M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Medical | 5 | 63% |
| Therapeutics | 3 | 38% |
| Health Diagnostics | 2 | 25% |
| Hospital | 1 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Series B | 2 | 25% |
| Seed | 1 | 13% |
| Series C | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Taiwan | 6 | 75% |
| United States | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Allen Leu | Managing Director | 0 | https://shizune.co/investors/profile/allen-leu |
| Amy Huang | VP and Managing Director | 0 | https://shizune.co/investors/profile/amy-huang |
| Catherine Tsai | Managing Director | 0 | https://shizune.co/investors/profile/catherine-tsai |
| Chester Ho | CEO | 0 | https://shizune.co/investors/profile/chester-ho |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Primo Biotechnology | Primo Biotechnology harnesses advanced molecular imaging and radiopharmaceutical science to provide precise clinical information via targeted radiopharmaceuticals. Primo Biotechnology aims to form a patient-centric healthcare model and establish doctor-patient relationships founded on trust towards conveying hope and happiness to all patients. | $7.6M | Series A | Jul 02, 2025 |  |
| Elixiron Immunotherapeutics | Elixiron Immunotherapeutics is a company developing therapeutics for cancer, neurological diseases, and inflammatory disorders. |  | Series B | Jun 17, 2025 |  |
| AnBogen Therapeutics | Anbogen is a clinical-stage biotechnology company dedicated to developing precision anti-cancer drugs that hold the/promise of curing cancers and/or improving the lives of cancer patients worldwide. | $12.5M | Series A | Jan 31, 2024 |  |
| AnHorn Medicines | AnHorn Medicines is a drug discovery company that develops therapeutic medicines for cancer, neurodegeneration, and aging diseases. | $10M | Series A | Apr 25, 2023 |  |
| AcadeMab Biomedical | AcadeMab Biomedical focuses on antibody and mRNA vaccine development to treat human diseases and enhance human health and well-being. |  | Seed | Jan 01, 2022 |  |
| APRINOIA Therapeutics | APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $40M | Series C | Dec 28, 2021 |  |
| APRINOIA Therapeutics | APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau,alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston. | $11.1M | Series B | Jan 16, 2018 |  |
| Sapience Therapeutics | Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $22.5M | Series A | Jul 12, 2016 |  |

8 of 8 investments shown.

## Co-investors
- [Maxpro Ventures](https://shizune.co/investors/profile/maxpro-ventures) — VC Fund, 3 deals together
- [KTB Network](https://shizune.co/investors/profile/ktb-network-2) — VC Fund, 2 deals together
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund, 2 deals together
- [Bank SinoPac (Hong Kong)](https://shizune.co/investors/profile/bank-sinopac-hong-kong) — VC Fund, 1 deal together
- [Black Marble Capital Management](https://shizune.co/investors/profile/black-marble-capital-management) — VC Fund, 1 deal together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Taiwan](https://shizune.co/investors/health-care-vc-funds-taiwan)
- [All Investors in Taiwan](https://shizune.co/investors/investors-taiwan)
- [All VC Funds in Taiwan](https://shizune.co/investors/vc-funds-taiwan)
- [Medical Investors in Taiwan](https://shizune.co/investors/medical-investors-taiwan)
- [Medical VC Funds in Taiwan](https://shizune.co/investors/medical-vc-funds-taiwan)
- [Biotechnology Investors in Taiwan](https://shizune.co/investors/biotechnology-investors-taiwan)

## FAQ

### What does TaiAn Technologies invest in?

TaiAn Technologies invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in Taiwan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is TaiAn Technologies's check size?

TaiAn Technologies typically joins rounds of $7.6M–$23M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TaiAn Technologies participates in.

### How do I contact TaiAn Technologies?

Public channels for TaiAn Technologies include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at TaiAn Technologies?

The team at TaiAn Technologies includes Allen Leu (Managing Director), Amy Huang (VP and Managing Director) and Catherine Tsai (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co